Recombinant Human Erythropoietin to Correct Uremic Bleeding

American Journal of Kidney Diseases

Volumn 18, Issue 1, 1991, Pages 44-49

  Viganò, Gianluigi ^a,b   Benigni, Ariela ^a,b   Mendogni, Daniela ^a,b   Mingardi, Giulio ^a,b   Mecca, Giuliano ^a,b   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

anemia; bleeding time; Recombinant human erythropoietin; uremic bleeding

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; BLEEDING TIME; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; UREMIA;

EID: 0025778932     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(12)80289-7     Document Type: Article

References (22)

1. Coagulation abnormalities in uremia
2. Uremia as a cause of bleeding
3. Bleeding in renal failure
4. Bleeding in uremia: A useful test to assess clinical bleeding
5. Uraemic bleeding: Role of anaemia and beneficial effect of red cell transfusions
6. Low haematocrit and prolonged bleeding time in uraemic patients: Effect of red cell transfusions
7. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis
8. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a phase I and II clinical trial
9. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: Implications of erythropoietin therapy
10. Treatment of renal anemia with recombinant human erythropoietin
11. Statement on the clinical use of recombinant erythropoietin in anemia of end-stage renal disease
12. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin
13. Treatment of anaemia in haemodialysis patients with recombinant erythropoietin
14. Clinical trial of a new bleeding-time device
15. Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect
16. Red blood cells: Their dual role on thrombus formation
17. Components in blood viscosity. The relative contribution of haematocrit fibrinogen and other proteins
18. Enhanced platelet function and coagulability during treatment with recombinant erythropoietin (rEPO) in patients undergoing hemodialysis
19. The effect of bicarbonate and acetate hemodialysis on platelet cAMP and aggregation
20. Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation
21. Haemostatic effects of recombinant human erythropoietin in chronic haemodialysis patients